At a glance
ClinicalIndex Comparison RecordN/ACompleted· 81 enrolled
Drug / intervention
TetraGraphdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Flexor Hallicus Brevis and Adductor Pollicis as Sites for Neuromuscular Monitoring With Electromyography (Thumb vs Great Toe) After Sugammadex Administration
In Brief
A clinical study evaluating TetraGraph for Residual Neuromuscular Blockade. Completed, enrolled 81 participants across 1 site.
Detailed Summary
Researches are comparing the accuracy of measuring muscle relaxation in the thumb versus the great toe.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsResidual Neuromuscular Blockade
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartAug 2020
Primary CompletionJan 2021
TodayJul 2026
First PostedMar 18, 2020
Enrollment StartAug 18, 2020
Primary CompletionJan 19, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 6.3 years ago
Interventions
TetraGraphdevice
FDA approved neuromuscular transmission monitor capable of measuring the depth of neuromuscular block in anesthetized patients who received neuromuscular blocking agents. TetraGraph uses EMG to measure the muscle action potentials that are generated in response to electrical neurostimulation via skin (ECG) electrodes.